Company news

CelLBxHealth plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Streamlining of operations to increase cash runway

October 18, 2022

TR-1: Notification of major holdings

October 17, 2022

First regional distribution agreement

October 12, 2022

Positive headline results from ovarian study

September 29, 2022

Study using Parsortix in head and neck cancer

September 28, 2022

New poster presented at ASCP Meeting

September 13, 2022

Novel assay predicts malignancy in pelvic mass

September 12, 2022

Novel insight into metastasis in NSCLC patients

July 28, 2022

New study of Parsortix system in NSCLC

July 20, 2022

Director/PDMR Shareholding

July 19, 2022

Results of Capital Raise

July 15, 2022

Retail Offer via PrimaryBid

July 14, 2022

Result of 2022 Annual General Meeting

June 29, 2022

Spread of breast cancer accelerates during sleep

June 27, 2022

Secured contract from pharma services customer

June 22, 2022

Predicting immunotherapy response in SCLC

June 16, 2022

Potential role of invasive cellular protrusions

June 14, 2022

Partnership with major United States urology group

May 30, 2022

Molecular characterisation of CTCs

May 27, 2022

ANGLE receives FDA clearance for Parsortix

May 25, 2022

Prostate Cancer UK funds new study using Parsortix

May 20, 2022

Poster on Parsortix system presented at AACR 2022

April 14, 2022

Identifying drug targets in cancer metastasis

April 1, 2022

Rapid information on patient response to therapies

March 29, 2022

Identifying therapeutic targets in TNBC patients

March 25, 2022

Update on laboratory accreditation

March 15, 2022

Potential in immunotherapy treatment selection

January 21, 2022

Concordance of Parsortix with tissue biopsy

January 17, 2022

Update on lab accreditation and ovarian study

January 13, 2022

Insight into drug resistance in NSCLC

January 10, 2022

Parsortix in RNA analysis of CTCs as tool in NSCLC

December 1, 2021

Appointment of Chief Medical Officer

November 15, 2021

Participation at Jefferies healthcare conference

November 12, 2021

Parsortix system showcased at NCRI Festival

November 11, 2021

Change of Adviser

November 2, 2021

Parsortix demonstrates ability to isolate CTCs

September 27, 2021

Study shows use of Parsortix to assess PD-L1

September 22, 2021

Parsortix enables gene expression analysis in mPCa

September 20, 2021

Study highlights superior performance of Parsortix

August 9, 2021

Contract secured for bespoke assay development

July 28, 2021

Harvesting CTCs from brain metastasis patients

July 9, 2021

Result of AGM

June 30, 2021

Result of Accelerated Bookbuild

June 25, 2021

Accelerated bookbuild to raise up to £20m

June 24, 2021

Annual General Meeting update

June 18, 2021

Update on submission for FDA clearance

June 4, 2021

Potential to prevent breast cancer relapse

June 1, 2021

Parsortix demonstrates oesophageal cancer utility

May 20, 2021

Exercise of options and total voting rights

May 19, 2021

Parsortix study uncovers targets in TNBC patients

May 11, 2021

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 30 decks. Every deck is listed under its year.